IntrinsicIntrinsic
← All summaries

CBAK Energy Technology, Inc.

CBAT
Financials & Chart →

Business Summary

CBAK Energy Technology, Inc. is a manufacturer of new energy high power lithium and sodium batteries used in light electric vehicles, electric vehicles, energy storage such as residential energy supply and UPS application, and other high-power applications. The company also develops and manufactures NCM precursor and cathode materials through its subsidiary Hitrans. The filing describes the industry as intensely competitive, characterized by rapid technological changes and evolving industry standards, with the company targeting battery markets for light electric vehicles, electric vehicles, and energy storage.

The filing names major competitors by product type: for Model 26650/26700 batteries, competitors include Shandong Goldencell, EVPS, and Power Long Battery; for Model 32140, Gotion Hi-tech and EVE Battery; for Model 40135, EVE Battery, Great Power, and Do-Fluoride; for battery packs, Greenway and Ampace; and for cathode and precursor materials, Beijing Easpring, Ronbay Technology, and Huayou Cobalt. The company believes it competes favorably due to higher consistency and safety in product quality, leveraging cutting-edge battery manufacturing techniques and R&D capabilities.

The company generates revenue through two segments: production of high-power lithium and sodium battery cells, and manufacture and sale of materials used in high-power lithium battery cells. Revenue is recognized when the customer obtains control of promised goods, typically upon delivery. The company does not have long-term purchase commitments from customers; sales contracts for battery cells typically provide a non-binding three-month forecast, and for battery materials a non-binding two-month forecast, with lead times of 15 to 30 days for cells and 25 days for materials.

The company's primary battery portfolio includes lithium-ion cells (Models 26650, 26700, 32140, and 40135) and a 32140 sodium-ion cell. The lithium-ion models are suitable for light electric vehicles, residential energy storage, and UPS applications. The sodium-ion cells offer an 85% capacity retention rate at -40°C and can charge to 90% capacity in 10 minutes . The company is developing larger cylindrical battery models such as 60115, 60135, and 60150. Through Hitrans, the company manufactures NCM cathode materials and precursors, which are crucial raw materials for lithium-ion batteries.

Net revenues from sales of batteries for residential energy supply and uninterruptable supplies were $68.8 million for fiscal year 2025, compared to $124.6 million for fiscal year 2024. Net revenues from sales of cathode materials and precursors were $89.2 million for fiscal year 2025, compared to $40.0 million for fiscal year 2024. Net revenues from sales of batteries for light electric vehicles were $36.4 million for fiscal year 2025, compared to $10.3 million for fiscal year 2024, an increase of 252% . Net revenues from sales of batteries for electric vehicles were $0.8 million for fiscal year 2025, compared to $1.7 million for fiscal year 2024.

Significant operational developments include the commencement of mass production for two new production lines at Phase II of the Nanjing Project, adding 3.0 GWh of annual capacity, with full capacity of 3 GWh expected by early 2027. At the Dalian facility, mass production of the new model 40135 line with a designed capacity of 2.3 GWh commenced in 2025, with total production capacity projected to reach 3.3 GWh by early 2027. Hitrans is constructing a new 10,000-metric-ton cathode manufacturing plant, slated for completion in September 2026, and has completed construction of a new precursor plant with a capacity of 37,000 metric tons , anticipated to commence production in 2027. In November 2025, CBAK New Energy acquired an additional 6.1% equity interest in Hitrans for RMB 21.07 million (approximately $3.0 million) , increasing ownership to 73.46% of registered equity interests (representing 79.64% of paid-up capital). The company also initiated a battery pack integration operation through Nanjing BFD, targeting the African market for light electric vehicle battery swapping infrastructure. On May 20, 2025, the board authorized a stock repurchase program of up to $20 million , ending May 20, 2026. The company repurchased 1,457,456 shares for $1.5 million at an average price of $1.14 per share.

Total net revenues were $195.2 million for fiscal year 2025, compared to $176.6 million for fiscal year 2024, an increase of 11% . Gross profit was $18.4 million , or 9.4% of net revenues, compared to $41.8 million , or 24% of net revenues, in the prior year. The company recorded a net loss of $10.4 million (net loss attributable to shareholders of $9.4 million ) for fiscal year 2025, compared to net income of $9.6 million (net income attributable to shareholders of $11.8 million ) in fiscal year 2024. As of December 31, 2025, the company had an accumulated deficit of $133.8 million and net assets of $109.5 million .

Business Outlook

A primary growth vector is the expansion of manufacturing capacity. The Nanjing Project aims for a total production capacity of approximately 20 GWh per year after completion. Phase II aims to add three large manufacturing plants and augment annual production capacity by an additional 18 GWh . The first two production lines at Phase II, with a combined capacity of 3.0 GWh , are in ramp-up, with full capacity expected by early 2027. The Dalian facility's new model 40135 line adds 2.3 GWh of design capacity, with total Dalian capacity projected to reach 3.3 GWh by early 2027. Hitrans is constructing a new 10,000-metric-ton cathode plant (completion September 2026, full operation first half 2027) and has completed a new 37,000-metric-ton precursor plant (production anticipated in 2027). The company is also developing next-generation large-format cylindrical batteries (Models 60115, 60135, 60150) to capture demand in LEV and energy storage sectors.

Another growth vector is geographic expansion, particularly into the African market. In 2025, Nanjing BFD initiated battery pack integration operations targeting the African market for light electric vehicle battery swapping infrastructure, with approximately 9% of revenue derived from Africa in 2025. The company is also accelerating its global footprint by developing international distribution channels across Europe, North America, Southeast Asia, and South Asia. The company's R&D team is developing larger cylindrical battery models (60115, 60135, 60150) and focusing on high-nickel low-cobalt materials and single-crystal high-voltage products. The company also established a subsidiary in Malaysia in April 2025 to focus on manufacturing and sales of cylindrical lithium cells for overseas markets.

The filing discusses margin trajectory in the context of product mix changes. Gross profit margin declined significantly from 24% in fiscal 2024 to 9.4% in fiscal 2025, attributed to a substantial drop in sales of higher-margin residential energy supply batteries. Management expects gross profit margins to gradually recover upon the upgrade from Model 26650 to Model 40135 at the Dalian facility. The company anticipates that the highly optimized capacity expansion will drive sustained margin expansion and profitability across the battery segment.

The company is investing in the construction of a larger, next-generation R&D center as a primary initiative within the Phase II Nanjing Project. Capital expenditures were $44.6 million in fiscal 2025, primarily allocated to construction of Dalian, Nanjing, Zhejiang, and Anhui facilities. Management estimates total capital expenditures in fiscal year 2026 will reach approximately $50 million , to be used for constructing new plants with new production lines and battery module packing lines. The company had 1,739 employees as of December 31, 2025, with 379 in R&D.

R&D spending was $15.8 million for fiscal year 2025, compared to $13.0 million in fiscal 2024. The company has a stock repurchase program authorized on May 20, 2025 for up to $20 million , ending May 20, 2026. As of December 31, 2025, approximately $18.5 million remained available under the program. The company has never declared or paid any dividends and has no present plan to pay cash dividends in the foreseeable future.

The filing identifies several headwinds. The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern due to a working capital deficiency, accumulated deficit from recurring net losses, and significant short-term debt obligations maturing in less than one year as of December 31, 2025. The company faces intense competition from other battery manufacturers and cathode material producers, many with significantly greater resources. The company is dependent on a limited number of customers, with top five customers accounting for approximately 37.1% of revenues in fiscal 2025. The company also faces risks associated with international operations, including in new markets such as Africa, and risks related to the PRC government's substantial influence over business activities and changes in U.S.-China relations.

The filing identifies structural constraints including the natural lifecycle of the Model 26650 battery (introduced in 2006), which is nearing the end of its lifecycle and experiencing contracting market share. The company is redirecting capital expenditure away from 26650 lines. The company also faces risks from fluctuations in raw material prices (Ni, Co, Mn, Li2CO3, LiPF6, LiFePO4) and the inability to fully offset higher costs through price increases. The company does not have long-term purchase commitments from customers, and its sales contracts typically have terms of one year or less.

Risk Factors

The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern, citing a working capital deficiency, accumulated deficit of $133.8 million from recurring net losses, and significant short-term debt obligations maturing in less than one year as of December 31, 2025. The company is dependent on a limited number of customers, with top five customers accounting for approximately 37.1% of revenues in fiscal 2025, and this dependence is likely to continue. The company faces intense competition from other battery manufacturers and cathode material producers, many with significantly greater resources. The company and its independent public accounting firm identified material weaknesses in internal control over financial reporting as of December 31, 2025, including a lack of appropriate policies and procedures to evaluate proper accounting and disclosures of key documents and agreements, and insufficient skilled accounting personnel with appropriate U.S. GAAP knowledge. The company's expansion into the African market subjects it to significant operational, regulatory, political, and economic risks, including limited infrastructure, evolving regulatory frameworks, political instability, and currency volatility.

Management Priorities

Management's message emphasizes the company's strategic transition to next-generation battery models and capacity expansion to meet robust demand. Key themes include the successful ramp-up of new production lines for Model 32140 at Nanjing and Model 40135 at Dalian, with full capacity utilization expected by early 2027. Management highlights the acquisition of additional equity in Hitrans and its recovery trend, with net revenue from cathode materials and precursors increasing from $40.0 million for fiscal 2024 to $89.2 million for fiscal 2025. The company is also focusing on the development of larger cylindrical battery models (60115, 60135, 60150) and sodium-ion technology. Management expresses confidence in securing additional orders from the expanding new energy market and expects the capacity expansion to drive sustained margin expansion and profitability. The company is also pursuing a redomicile merger to the Cayman Islands, expected to be completed in the first half of 2026, to reduce costs and align corporate structure with its international strategy.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Development of New Battery Models
  2. [2] Item 7, MD&A — Results of Operations
  3. [3] Item 7, MD&A — Results of Operations
  4. [4] Item 7, MD&A — Results of Operations
  5. [5] Item 7, MD&A — Results of Operations
  6. [6] Item 7, MD&A — Results of Operations
  7. [7] Item 7, MD&A — Results of Operations
  8. [8] Item 7, MD&A — Results of Operations
  9. [9] Item 7, MD&A — Results of Operations
  10. [10] Item 7, MD&A — Results of Operations
  11. [11] Item 1, Business — Expansion of Manufacturing Capabilities
  12. [12] Item 1, Business — Expansion of Manufacturing Capabilities
  13. [13] Item 1, Business — Expansion of Manufacturing Capabilities
  14. [14] Item 1, Business — Expansion of Manufacturing Capabilities
  15. [15] Item 1, Business — Expansion of Manufacturing Capabilities
  16. [16] Item 1, Business — Expansion of Manufacturing Capabilities
  17. [17] Item 1, Business — Acquisition of a Raw Materials Manufacturer
  18. [18] Item 1, Business — Acquisition of a Raw Materials Manufacturer
  19. [19] Item 1, Business — Acquisition of a Raw Materials Manufacturer
  20. [20] Item 1, Business — Acquisition of a Raw Materials Manufacturer
  21. [21] Item 5, Market for Registrant's Common Equity — Issuer Purchases of Equity Securities
  22. [22] Item 8, Financial Statements — Consolidated Statements of Changes in Shareholders' Equity
  23. [23] Item 8, Financial Statements — Consolidated Statements of Changes in Shareholders' Equity
  24. [24] Item 8, Note 1 — Principal Activities, Basis of Presentation and Organization
  25. [25] Item 1, Business — Overview of Our Business
  26. [26] Item 1, Business — Overview of Our Business
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 1, Business — Overview of Our Business
  33. [33] Item 8, Financial Statements — Consolidated Statements of Operations
  34. [34] Item 1, Business — Overview of Our Business
  35. [35] Item 8, Financial Statements — Consolidated Statements of Operations
  36. [36] Item 1, Business — Overview of Our Business
  37. [37] Item 1, Business — Overview of Our Business
  38. [38] Item 1, Business — Expansion of Manufacturing Capabilities
  39. [39] Item 1, Business — Expansion of Manufacturing Capabilities
  40. [40] Item 1, Business — Expansion of Manufacturing Capabilities
  41. [41] Item 1, Business — Expansion of Manufacturing Capabilities
  42. [42] Item 1, Business — Expansion of Manufacturing Capabilities
  43. [43] Item 1, Business — Expansion of Manufacturing Capabilities
  44. [44] Item 1, Business — Expansion of Manufacturing Capabilities
  45. [45] Item 1A, Risk Factors — Risks Related to Our Business
  46. [46] Item 7, MD&A — Results of Operations
  47. [47] Item 7, MD&A — Results of Operations
  48. [48] Item 7, MD&A — Capital Expenditures
  49. [49] Item 7, MD&A — Capital Expenditures
  50. [50] Item 1, Business — Human Capital
  51. [51] Item 1, Business — Human Capital
  52. [52] Item 7, MD&A — Results of Operations
  53. [53] Item 7, MD&A — Results of Operations
  54. [54] Item 5, Market for Registrant's Common Equity — Issuer Purchases of Equity Securities
  55. [55] Item 5, Market for Registrant's Common Equity — Issuer Purchases of Equity Securities
  56. [56] Item 1A, Risk Factors — Risks Related to Our Business
  57. [57] Item 1, Business — Overview of Our Business
  58. [58] Item 1A, Risk Factors — Risks Related to Our Business
  59. [59] Item 1A, Risk Factors — Risks Related to Our Business
  60. [60] Item 1A, Risk Factors — Risks Related to Our Business
  61. [61] Item 8, Financial Statements — Consolidated Statements of Operations
  62. [62] Item 8, Financial Statements — Consolidated Statements of Operations
  63. [63] Item 8, Financial Statements — Consolidated Statements of Operations
  64. [64] Item 8, Financial Statements — Consolidated Statements of Operations
  65. [65] Item 8, Financial Statements — Consolidated Statements of Operations
  66. [66] Item 8, Financial Statements — Consolidated Statements of Operations
  67. [67] Item 8, Financial Statements — Consolidated Statements of Operations
  68. [68] Item 7, MD&A — Results of Operations
  69. [69] Item 8, Financial Statements — Consolidated Statements of Operations
  70. [70] Item 7, MD&A — Results of Operations
  71. [71] Item 8, Financial Statements — Consolidated Statements of Operations
  72. [72] Item 8, Financial Statements — Consolidated Statements of Operations
  73. [73] Item 8, Financial Statements — Consolidated Statements of Cash Flows
  74. [74] Item 8, Financial Statements — Consolidated Statements of Cash Flows
  75. [75] Item 8, Financial Statements — Consolidated Statements of Cash Flows
  76. [76] Item 8, Financial Statements — Consolidated Balance Sheets
  77. [77] Item 8, Financial Statements — Consolidated Balance Sheets
  78. [78] Item 7, MD&A — Liquidity and Capital Resources
  79. [79] Item 8, Financial Statements — Consolidated Balance Sheets
  80. [80] Item 8, Financial Statements — Consolidated Balance Sheets
  81. [81] Item 7, MD&A — Results of Operations
  82. [82] Item 7, MD&A — Results of Operations
  83. [83] Item 7, MD&A — Results of Operations
  84. [84] Item 7, MD&A — Results of Operations

Analysis on 6/21/2026